Ventricular Assist Devices Global Market Report 2023: Sector to Reach $2.88 Billion by 2031 at a 7.9% CAGR
02 mai 2023 07h23 HE
|
Research and Markets
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Ventricular Assist Devices Market by Product, Application, Design, Age: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been...
New Study with Abiomed’s Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery
30 juin 2017 08h04 HE
|
Abiomed
DANVERS, Mass., June 30, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the recent publication of a...
Abiomed Introduces 3rd Generation Impella CP® Heart Pumps at SCAI 2017
09 mai 2017 09h33 HE
|
Abiomed
DANVERS, Mass., May 09, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced the debut of the 3rd Generation...
First-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Cardiology Scientific Session
19 mars 2017 14h30 HE
|
Abiomed
- Real-World Data Representing 15,259 Patients WASHINGTON, March 19, 2017 (GLOBE NEWSWIRE) -- Data from Abiomed’s (NASDAQ:ABMD) Impella® Quality (IQ) Assurance Program, which includes the IQ...
Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session With More Than 10 Presentations
16 mars 2017 08h00 HE
|
Abiomed
DANVERS, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 10...
New Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
09 mars 2017 08h00 HE
|
Abiomed
DANVERS, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- A new study published in Circulation Research finds use of hemodynamic support with Impella® 2.5 heart pump during high-risk percutaneous coronary...
Abiomed Surpasses 50,000 Impella® Patients Treated in the United States
23 févr. 2017 14h00 HE
|
Abiomed
DANVERS, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced that it has supported more than 50,000...